Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition-Reference-Cited by-同舟云学术

Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition

Published:2016-05-20 Issue:1 Volume:7 Page:
ISSN:2041-1723
Container-title:Nature Communications
language:en
Short-container-title:Nat Commun

Author:

Burger Jan A.,Landau Dan A.,Taylor-Weiner Amaro,Bozic Ivana,Zhang Huidan,Sarosiek Kristopher^ORCID,Wang Lili,Stewart Chip,Fan Jean^ORCID,Hoellenriegel Julia,Sivina Mariela,Dubuc Adrian M.,Fraser Cameron,Han Yulong,Li Shuqiang,Livak Kenneth J.,Zou Lihua^ORCID,Wan Youzhong,Konoplev Sergej,Sougnez Carrie,Brown Jennifer R.,Abruzzo Lynne V.^ORCID,Carter Scott L.,Keating Michael J.,Davids Matthew S.,Wierda William G.,Cibulskis Kristian,Zenz Thorsten,Werner Lillian,Cin Paola Dal,Kharchencko Peter,Neuberg Donna^ORCID,Kantarjian Hagop,Lander Eric,Gabriel Stacey,O’Brien Susan,Letai Anthony,Weitz David A.,Nowak Martin A.,Getz Gad,Wu Catherine J.

Publisher

Springer Science and Business Media LLC

Subject

General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry

Link

http://www.nature.com/articles/ncomms11589.pdf

Reference45 articles.

1. Burger, J. A. & Chiorazzi, N. B cell receptor signaling in chronic lymphocytic leukemia. Trends Immunol. 34, 592–601 (2013).

2. Friedberg, J. W. et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 115, 2578–2585 (2010).

3. Byrd, J. C. et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 369, 32–42 (2013).

4. Furman, R. R. et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 370, 997–1007 (2014).

5. Honigberg, L. A. et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc. Natl Acad. Sci. USA 107, 13075–13080 (2010).

Cited by 282 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Transcriptomic and proteomic differences in BTK-WT and BTK-mutated CLL and their changes during therapy with pirtobrutinib;Blood Advances;2024-08-28

2. Monitoring Response and Resistance to Treatment in Chronic Lymphocytic Leukemia;Cancers;2024-05-28

3. A Review of Resistance Mechanisms to Bruton’s Kinase Inhibitors in Chronic Lymphocytic Leukemia;International Journal of Molecular Sciences;2024-05-11

4. Prognostication in chronic lymphocytic leukemia;Seminars in Hematology;2024-04

5. Oncogenic MTOR Signaling Axis Compensates BTK Inhibition in a Chronic Lymphocytic Leukemia Patient with Richter Transformation: A Case Report and Review of the Literature;Acta Haematologica;2024-02-24